Candel Therapeutics (CADL) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Candel Therapeutics (CADL) has outperformed REGENXBIO (RGNX) over the past year, gaining 10.8% versus a loss of 39.3%. Over five years, CADL leads with a -48.5% price change compared with -76.9% for RGNX. REGENXBIO is the larger company by market cap ($473.4 million vs $395.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | RGNX |
|---|---|---|
| Share price | $5.04 | $7.16 |
| Market cap | $395.37M | $473.44M |
| 1-day change | -1.75% | -0.28% |
| YTD return | -10.80% | -50.28% |
| 1-year return | +10.77% | -39.32% |
| 5-year return | -48.47% | -76.87% |
| EPS (TTM) | $-1.53 | $-3.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $170.44M |
| Revenue growth (YoY) | — | +104.54% |
| Net income (latest FY) | $-38.18M | $-193.88M |
| Operating margin | — | -94.58% |
| Net margin | — | -113.75% |
| 52-week high | $14.00 | $16.19 |
| 52-week low | $4.35 | $5.46 |
| Distance from 52-week high | -64.00% | -55.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +250.60% | +198.88% |
| Average volume | 1.26M | 1.39M |
| Shares outstanding | 78.45M | 66.12M |
| Employees | 55 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed RGNX by 50.1 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
CADL vs RGNX FAQ
Which is bigger, Candel Therapeutics or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $473.44M compared with $395.37M for Candel Therapeutics (CADL).
Which stock has performed better over the past year, CADL or RGNX?
CADL returned +10.77% over the past 12 months, compared with -39.32% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and REGENXBIO in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.